[Treatment of recurrent malignant gliomas by surgery combined with recombinant adenovirus-p53 injection].
OBJECTIVE
To evaluate the efficacy and toxicity of combination therapy with surgery and recombinant adenovirus-p53 injection of recurrent malignant gliomas.


METHODS
38 patients with recurrent malignant gliomas were included in this study. Among them, 18 patients of combined treatment group had Ommaya reservoirs placed into the tumor cavities after the resection of the tumors and received regular recombinant adenovirus-p53 injections after the operation. The other 20 patients received surgery alone.


RESULTS
The 6-month and 1-year survival rates after the combination therapy were 66.7% (14/18) and 44.4% (8/18), respectively. The median survival time was 9.7 months. Compared with the surgery-alone group, the combined treatment group achieved significant improvement (P < 0.05). The Karnofsky score was significantly improved at 6 months after the combination therapy compared with that before the treatment (P < 0.05).


CONCLUSIONS
The recombinant adenovirus-p53 injection is safe and effective in treatment of recurrent malignant gliomas. The combination therapy of surgery and recombinant adenovirus-p53 injection may improve the life quality and the prognosis in patients with recurrent malignant gliomas.
Department of Neurosurgery, Liaocheng Brain Hospital, Liaocheng 252000, China.
Jian-xin
JX
Zhu
Zhong-min
ZM
Li
Feng-yang
FY
Geng
Qiang
Q
Fu
Chuan-jun
CJ
Guo
Yi-lei
YL
Xiao
Zhi-ti
ZT
Zhang
Gang
G
Li
D000256:Adenoviridae / Q000235:genetics; D000328:Adult; D001932:Brain Neoplasms / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D016158:Genes, p53; D015316:Genetic Therapy; D005910:Glioma / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011994:Recombinant Proteins / Q000627:therapeutic use*; D015996:Survival Rate; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000627:therapeutic use*
D011994:Recombinant Proteins; D016159:Tumor Suppressor Protein p53